Ever Supreme Bio Technology Co., Ltd
Taipei ExchangeTotal Valuation
Ever Supreme Bio Technology Co., Ltd carries a market capitalization of 16.43B, placing it among publicly traded companies globally. Its enterprise value stands at 14.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16.43B |
| Enterprise Value | 14.08B |
Share Statistics
Ever Supreme Bio Technology Co., Ltd currently has 91.98M shares outstanding.
| Shares Outstanding | 91.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Ever Supreme Bio Technology Co., Ltd trades at a trailing price-to-earnings ratio of 33.70. The price-to-sales ratio is 14.22, and the price-to-book ratio stands at 14.46.
| PE Ratio | 33.70 |
| PS Ratio | 14.22 |
| PB Ratio | 14.46 |
| P/TBV Ratio | 9.56 |
| P/FCF Ratio | 26.70 |
| P/OCF Ratio | 26.98 |
Enterprise Valuation
On an enterprise value basis, Ever Supreme Bio Technology Co., Ltd trades at an EV/EBITDA multiple of 32.07 and an EV/FCF ratio of 25.93. The EV/Sales ratio of 13.83 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 32.07 provides insight into valuation relative to core operating earnings.
| EV / Sales | 13.83 |
| EV / EBITDA | 32.07 |
| EV / EBIT | 32.07 |
| EV / FCF | 25.93 |
Financial Position
Ever Supreme Bio Technology Co., Ltd maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.54, indicating elevated leverage, while an interest coverage ratio of 478.66 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.78 |
| Quick Ratio | 1.03 |
| Debt / Equity | 2.54 |
| Debt / EBITDA | 0.09 |
| Interest Coverage | 478.66 |
Financial Efficiency
Ever Supreme Bio Technology Co., Ltd posts a return on equity of 39.30 and a return on invested capital of 20.68.
| Return on Equity (ROE) | 39.30 |
| Return on Assets (ROA) | 20.74 |
| Return on Invested Capital (ROIC) | 20.68 |
| Return on Capital Employed (ROCE) | 38.64 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.80 |
Taxes
Over the trailing twelve months, Ever Supreme Bio Technology Co., Ltd has paid 94.90M in income taxes, reflecting an effective tax rate of 18.10.
| Income Tax | 94.90M |
| Effective Tax Rate | 18.10 |
Stock Price Statistics
Ever Supreme Bio Technology Co., Ltd's stock has gained approximately 10.83659% over the past 52 weeks. The 50-day moving average sits at 136.57, while the 200-day moving average is 146.86.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.83659% |
| 50-Day Moving Average | 136.57 |
| 200-Day Moving Average | 146.86 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ever Supreme Bio Technology Co., Ltd generated 1.02B in revenue and converted that into 429.43M in net income, yielding earnings per share of 4.63. EBITDA reached 438.94M, while operating income came in at 438.94M.
| Revenue | 1.02B |
| Gross Profit | 721.33M |
| Operating Income | 438.94M |
| Pretax Income | 524.33M |
| Net Income | 429.43M |
| EBITDA | 438.94M |
| EBIT | 438.94M |
| Earnings Per Share (EPS) | 4.63 |
Balance Sheet
Ever Supreme Bio Technology Co., Ltd holds 435.66M in cash and equivalents against 38.75M in total debt, resulting in a net debt position of -222.16M. Total book value stands at 1.00B, with working capital of 330.14M providing operational flexibility.
| Cash & Cash Equivalents | 435.66M |
| Total Debt | 38.75M |
| Net Debt | -222.16M |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 10.80 |
| Working Capital | 330.14M |
Cash Flow
Ever Supreme Bio Technology Co., Ltd produced 536.35M in operating cash flow over the past twelve months. After subtracting -5.72M in capital expenditures, free cash flow totaled 530.62M - equivalent to 5.73 per share.
| Operating Cash Flow | 536.35M |
| Capital Expenditures | -5.72M |
| Free Cash Flow | 530.62M |
| FCF Per Share | 5.73 |
Margins
Ever Supreme Bio Technology Co., Ltd operates with a gross margin of 70.89, reflecting its pricing power and cost economics. The operating margin of 43.14 and net profit margin of 42.20 provide insight into operational efficiency.
| Gross Margin | 70.89 |
| Operating Margin | 43.14 |
| Pretax Margin | 51.53 |
| Profit Margin | 42.20 |
| EBITDA Margin | 43.14 |
Dividends & Yields
The company's payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 0.00 |
| Shareholder Yield | 5.18 |
| FCF Yield | 3.75 |
Stock Splits
Ever Supreme Bio Technology Co., Ltd's most recent stock split took place on May 14, 2026 with a 20:21 split ratio.
| Last Split Date | 5/14/2026 |
| Split Ratio | 20:21 |
Scores
Ever Supreme Bio Technology Co., Ltd posts an Altman Z-Score of 19.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 19.70 |